Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.

@article{Costa2013TrendsIU,
  title={Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.},
  author={Luciano J Costa and Mei-Jie Zhang and Xiaobo Zhong and Angela Dispenzieri and Sagar Lonial and Amrita Y. Krishnan and Cesar Freytes and David H Vesole and Robert Peter Gale and Kenneth A. Anderson and Baldeep Mona Wirk and Bipin N Savani and Edmund K Waller and Harry Schouten and Hillard M Lazarus and Kenneth R. Meehan and M. Ramakrishna Sharma and Rammurti T. Kamble and Ravi Vij and S K Praveen Kumar and Taiga Nishihori and Tamila L. Kindwall-Keller and Wael Saber and Parameswaran N. Hari},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  year={2013},
  volume={19 11},
  pages={1615-24}
}
The impact of novel drugs for treating multiple myeloma (MM) on the utilization and outcomes of autologous hematopoietic progenitor cell transplantation (AHPCT) is unknown. We reviewed characteristics and outcomes of 20,278 patients who underwent AHPCT within 12 months of diagnosis of MM in the United States and Canada and registered at the Center for International Blood and Marrow Transplant Research (CIBMTR) in 3 time cohorts reflecting the increasing availability of novel drugs: 1995 to 1999… CONTINUE READING